Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

EGAS00001002935-sc-2019-04-11T08:44:26Z - samples

ABSTRACT: We aim to describe the transcriptomic landscape of infant spindle cell tumours. . This dataset contains all the data available for this study on 2019-04-11.

PROVIDER: EGAD00001004954 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Infant Spindle Tumour Study

Project description:We aim to describe the transcriptomic landscape of infant spindle cell tumours.

| EGAS00001002935 | EGA

EGAS00001002929-sc-2019-04-11T08:44:19Z - samples

Project description:Single cell + bulk genomics study for immune and hematopoietic organs during human fetal development . This dataset contains all the data available for this study on 2019-04-11.

| EGAD00001004953 | EGA

EGAS00001002988-sc-2019-04-11T08:44:36Z - samples

Project description:The aim of this project is to test whether HPV oncogenes and /or interferon induce the APOBEC mutational signature in vitro, and to test the role of APOBEC3A in this process. . This dataset contains all the data available for this study on 2019-04-11.

| EGAD00001004955 | EGA

EGAS00001002863-sc-2019-04-11T08:44:10Z - samples

Project description:Small-molecule inhibitors targeting the most commonly activated pathway in melanoma, MAPK pathway (either alone or in combination) are already given to melanoma patients for few years, and initially reduce tumour burden dramatically, eventually melanomas become resistant and tumours progress while on treatment. Resistance to this treatment occurs by acquisition of additional mutations or other alterations that affect the mitogen-activated protein kinase (MAPK) pathway by either direct or indirect signalling. Many resistance mechanisms somehow lead to reactivation of extracellular signal-regulated kinase (ERK), thereby restoring signalling of the oncogenic BRAF/MEK/ERK pathway. In addition, PI3K pathway activation contributes to resistance to BRAF inhibition. Less frequent but equally important to the phenomenon of targeted drug resistance is the observation that B15-20% of BRAF mutant melanoma patients fail to respond to BRAF inhibition already early on treatment, owing to intrinsic resistance. These patients have little therapeutic options, unless immunotherapy can be given. To better understand the resistance mechanisms in MAPK inhibitor-treated melanoma patients and melanoma biology, our lab generated a big panel of MAPK inhibitor resistant melanoma cell lines by continuous drug exposure. The understanding of the genetic landscape and gene expression as well as cross resistance to other treatment regimens, and other aspects of melanoma biology such as phenotype switch, will allow us to better exploit new therapeutic strategies for melanoma patients. . This dataset contains all the data available for this study on 2019-04-11.

| EGAD00001004952 | EGA

Transcriptional profiling of mouse CRL-2019 cell line of MH-S cells treated with recombinant PVL versus untreated.

Project description:cDNA microarray of the cellline MH-S cells (ATCC: CRL-2019) that were treated with recombinant PVL (rPVL) versus untreated cells

2010-12-21 | E-MEXP-2513 | biostudies-arrayexpress

EGAS00001001852-sc-2019-04-11T08:43:29Z - samples

Project description:Whole-genome sequencing of human individuals from Polynesian and Native American populations, as well as 10x Genomics Chromium data from Polynesian, Native American and Aboriginal Australian populations, allowing for experimental phasing of haplotypes. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/ . This dataset contains all the data available for this study on 2019-04-11.

| EGAD00001004951 | EGA

Meloidogyne sp. RB-2019 isolate:RB-2019

Project description:Meloidogyne sp. RB-2019 isolate:RB-2019 Genome sequencing

| PRJNA556113 | ENA

EGAS00001002253-sc-2019-04-01T09:21:26Z - samples

Project description:Genome-wide CRISPR/Cas9 library screen was performed in isogenic cell lines. Three biological replicates were used. Cells were harvested at initiation of screen and at specific time points following cell culture. Using this approach we aim to identify genes specifically important in cell survival in engineered cell lines. Please perform 72, instead of 36, PCR reactions as the screen performed at 200x coverage. . This dataset contains all the data available for this study on 2019-04-01.

| EGAD00001004881 | EGA

Trial B 2019

Project description:Trial B 2019

| PRJEB32732 | ENA

EPD_2018-2019

Project description:EPD_2018-2019 Raw sequence reads

| PRJNA1056142 | ENA